...
首页> 外文期刊>Clinical rheumatology >Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial
【24h】

Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial

机译:痛风和高尿酸血症患者对胁迫治疗不良反应的预测因子:多中心随机试验的后HOC分析

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction Clinical guidelines have recommended a target of serum uric acid (SUA) level below 6.0 mg/dL for the urate-lowering therapy (ULT) of gout patients, but there are still a high proportion of patients failing to achieve the therapeutic target above. This study aimed to identify possible predictors of poor response to ULT in gout patients. Methods We performed a post-hoc analysis of a multicenter randomized double-blind trial which assessed the efficacy of febuxostat in patients with hyperuricemia (serum urate level >= 8.0 mg/dL) and gout. Demographic characters and baseline data including SUA levels were collected. Poor response to ULT was defined as average SUA after ULT was more than 6.0 mg/dL. Factors associated with poor response to ULT in gout patients were analyzed, and multivariate logistic regression analysis was also carried out to find out those independent predictors. Results A total of 370 patients were enrolled in this post-hoc analysis. Compared with those with good response to ULT, patients with poor response to ULT had younger age (P < 0.001), higher proportion of obesity (P = 0.003), higher proportion of statins use (P = 0.019), higher body mass index (BMI) (P < 0.001), higher baseline SUA (P < 0.001), higher proportion of males (P = 0.001), higher alanine transaminase (P < 0.001), higher aspartate transaminase (P = 0.017), higher total cholesterol (P = 0.005), higher triglyceride (P = 0.042), and higher low density lipoprotein (P = 0.037). Multivariate logistic regression analysis showed that younger age (odds ratio (OR) = 0.965, 95% CI 0.943-0.987, P = 0.002), higher BMI (OR = 1.133, 95% CI 1.049-1.224, P = 0.001), higher baseline SUA (OR = 1.006, 95% CI 1.002-1.009, P = 0.001), and no application of febuxostat therapy (OR = 0.41, 95% CI 0.25-0.68, P < 0.001) were independent predictors of poor response to ULT in patients with gout. Conclusion In patients with gout and hyperuricemia, younger age, higher BMI, and higher baseline SUA are predictors of poor response to ULT. These findings could help physicians better identify patients who may fail in ULT and give individualized treatment precisely.
机译:简介临床指南推荐了血清尿酸(SUA)水平低于6.0 mg / dl的痛风患者(ULT),但仍有高比例的患者未能达到上述治疗靶标。本研究旨在识别痛风患者对ULT的不良反应的可能预测因子。方法对多中心随机双盲试验进行了对多中心的后期分析,评估了Febuxostat对高尿酸血症患者的疗效(血清尿液水平> = 8.0mg / dl)和痛风。收集了包括SUA水平的人口统计字符和基线数据。在ULT超过6.0mg / dl后,对ULT的反应差定义为平均SUA。分析了与痛风患者ULT的差的差的因素进行了分析,并且还进行了多变量逻辑回归分析,以找出那些独立的预测因子。结果共有370名患者参加了该后的HOC分析。与乌尔特良好反应的人相比,对ULT的反应差的患者具有较小的年龄(P <0.001),肥胖比例较高(P = 0.003),均少比例使用(P = 0.019),更高的体重指数( BMI)(P <0.001),较高的基线SUA(P <0.001),雄性比例较高(P = 0.001),较高的丙氨酸转氨酶(P <0.001),较高的天冬氨酸转氨酶(P = 0.017),总胆固醇更高(P = 0.005),较高的甘油三酯(P = 0.042),更高的低密度脂蛋白(P = 0.037)。多变量逻辑回归分析表明,年龄较小(差距(或)= 0.965,95%CI 0.943-0.987,P = 0.002),更高的BMI(或= 1.133,95%CI 1.049-1.224,P = 0.001),更高的基线SUA(或= 1.006,95%CI 1.002-1.009,P = 0.001),无需施用Febuxostat疗法(或= 0.41,95%CI 0.25-0.68,P <0.001)是对患者ULT不良反应的独立预测因子用痛风。结论患有痛风和高尿酸血症,较小的年龄,更高的BMI和高等基线SUA的患者是对ULT不良反应的预测因子。这些发现可以帮助医生更好地识别可能在ult中失效的患者,并准确地给予个体化治疗。

著录项

  • 来源
    《Clinical rheumatology》 |2019年第12期|共9页
  • 作者单位

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

    Qingdao Univ Affiliated Hosp 16 Jiangsu Rd Qingdao 266003 Shandong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内科学;
  • 关键词

    Gout; Predictors; Treatment outcomes; Urate-lowering therapy;

    机译:痛风;预测因子;治疗结果;降低治疗治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号